Task Force's Prevention Advice Proves Hard to Swallow by Marshall, E.
VIRGINIA MOYER, A PEDIATRICIAN WITH A 
keen interest in health screening, remem-
bers what it was like to be on the U.S. Pre-
ventive Services Task Force (USPSTF) 
before it became notorious—back when 
“we felt like we were toiling in obscurity.” 
Created by the Department of Health and 
Human Services (HHS) 3 decades ago, the 
panel examines clinical data and decides 
whether methods of preventing disease—
many of them already in use—are backed 
by evidence that they’re worth using. 
Moyer’s USPSTF term began in 2003 and 
except for a 2-year break, she has served 
ever since, becoming its chair in 2011. It 
was in 2009 that she and the rest of the task 
force shed their relative anonymity when 
they addressed a question many had thought 
settled: Should healthy women in their 40s 
get an annual mammogram?
The panel’s explosive answer: No, 
because giving such advice would do more 
harm than good. It would lead to a huge 
number of false alarms and biopsies, the 
16-member task force found, but would do 
little to reduce cancer deaths. 
That’s not how the panel worded its con-
clusion, however. Using carefully honed 
metrics, it gave a “C” grade (meaning weak) 
to evidence for benefi ts of mammography 
in this age group, a topic the task force had 
studied in various ways for years. After fail-
ing to agree on a fi rst vote, USPSTF had 
commissioned new modeling studies to 
clarify risks and benefi ts. Then the majority 
voted “against” a proposed recommendation 
that 40-year-olds get annual mammograms.
Turmoil ensued. Congressional com-
mittees grilled USPSTF members—nearly 
all of whom were physicians or nurses, and 
many of whom had Ph.D.s. Critics hastened 
to point out that none were cancer special-
ists. Advocates of mammography com-
plained that a nerdy committee was trying to 
cut medical benefi ts. Radiologists claimed 
that, maybe because panel members didn’t 
work directly with cancer patients, they 
under valued the lifesaving power of mam-
mography. Kathleen Sebelius, the HHS 
secretary, went on television to urge calm, 
arguably undercutting the panel by asking 
women to “do what you’ve always done: … 
Talk to your doctor” (Science, 19 February 
2010, p. 936). 
The noisy response was partly the result 
of bad timing, says Moyer, a professor at 
Baylor College of Medicine in Houston, 
Texas. The task force issued its f inding 
in the fall of 2009 when debate over the 
Administration’s health care reform was 
raging and congressional election cam-
paigns were heating up. It was a “perfect 
storm,” agrees epidemiologist J. Michael 
McGinnis, an advocate of preventive health 
care and senior scholar at the Institute of 
Medicine in Washington, D.C.
USPSTF touched off another furor in 
May 2012 when it voted to reject a widely 
used method of screening for prostate can-
cer: the blood test based on prostate-specifi c 
antigen (PSA). In this case, USPSTF found 
strong negative evidence and concluded that 
routine screening of healthy men should 
stop. Urologists were outraged; since then, 
their professional associations have urged 
Congress to overhaul USPSTF. They want 
medical specialists like themselves seated 
on future USPSTF panels.
McGinnis says he expected some storms 
both within and outside government when, 
as a top HHS offi cial, he created USPSTF 
in 1984. That’s why HHS set it up as an 
independent body: “We wanted them to be 
totally unfettered by anything but the evi-
dence in the way they went about their busi-
ness.” But the nature of controversy has 
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iodine plays a crucial role in the 
development of the body and the 
brain; a defi ciency can lead to 
mental retardation, cretinism, and 
thyroid problems. Switzerland was 
the fi rst to introduce iodized salt, 
in 1922, as a way to help prevent 
these conditions, and the United 
States and many other countries 
would soon adopt the practice.
PASS THE SALT:
Scurvy, which was recognized as far back as Hippocrates, 
results from a defi ciency of vitamin C and prevents the formation of collagen. Scurvy 
was once a common problem for those on long marine voyages, killing more than a 
million sailors according to some estimates, but evidence slowly built that eating 
citrus fruits and other foods rich in vitamin C could prevent it. Ultimately, Britain’s 
1867 Merchant Shipping Act would mandate that sailors in the country’s Royal 
Navy or Merchant Navy receive a daily ration of lime or lemon juice to prevent the condition.
Vaccines for infectious pathogens, often mandatory, are a widespread method of preventing diseases 
in a population, but organizations and countries have also tackled noncommunicable diseases with a 
variety of public health measures. Here are some notable examples.
C-ING OFF SCURVY:
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obesity, heart disease, 
and diabetes are all 
increasing worldwide, and 
many nutritionists lay the blame 
on eating too much food laden with sugar and fats. Last year, 
Denmark sought to curb poor nutrition by making certain prod-
ucts more expensive, introducing a tax adjusted to the saturated 
fat content on products such as butter, milk, cheese, pizza, meat, 
oil, and processed foods.
A TAXING 
EFFORT:
Cavities, or caries, 
result when an infection—usually bacterial—
demineralizes teeth, but more than a century ago 
researchers began to explore whether fl uoride 
in water could stymie that process. After a 
study in a Michigan city showed that fl uori-
dating the water supply reduced tooth decay 
among residents, U.S. offi cials backed the 
prevention strategy in 1951. Water fl uorida-
tion would soon become widespread in the 
United States and many other countries, 
though some worry about its other health 
implications or argue it infringes their rights.
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changed since the 1980s. When USPSTF 
began, McGinnis says, he imagined that it 
would highlight the benefi ts of preventive 
services, “to show that the evidence base for 
prevention was even stronger than for many 
treatment interventions.” At the time, clini-
cal medicine “was overwhelmingly focused 
on the treatment side,” McGinnis says.
McGinnis, who started in the Carter 
Administration and also served 
under presidents Ronald Reagan 
and Bill Clinton, agrees with Moyer 
that the 2009 storm over mammog-
raphy was partly about politics. But 
he says that experts were at odds, 
and that unlucky timing and “poor 
communication” of fi ndings con-
tributed to USPSTF’s woes. 
Ned Calonge, the physician-epidemiologist 
who was chair of USPSTF when it made its 
mammography recommendations in 2009, 
says that what really surprised him was being 
shut out of the subsequent public debate. “It 
was frustrating to me not being able to coun-
teract the very carefully crafted misinforma-
tion from the advocates” of mammography 
screening, says Calonge, now CEO of The 
Colorado Trust in Denver, a philanthropy. 
“We could not get control of the message.”
In its early days, USPSTF undertook 
two reviews of more than 150 preventive 
measures—trying to cover the universe, 
McGinnis says. But medicine was changing 
too rapidly to keep up this pace; in the late 
1990s the panel switched to doing analyses of 
single topics, which it now selects with input 
from researchers and the public. This year, 
for example, more than 20 topics are under 
review, from screening for abdominal aortic 
aneurysms to the use of vitamin D supple-
ments to prevent cancer and osteoporosis.
Calonge, Moyer, and McGinnis all say 
that USPSTF needs to learn to communi-
cate fi ndings more clearly. And they agree 
on another point: A bill proposed in Con-
gress this year to revamp USPSTF would 
not be a great way to improve scientific 
reviews. Introduced by Representative 
Marsha Blackburn (R–TN) and others, the 
USPSTF Transparency and Accountabil-
ity Act of 2012 (H.R. 5998) would require 
the task force to include “stakeholders” 
and “specialty care providers” 
on decision-making panels. This 
is the plan backed by urological 
associations.
Moyer acknowledges that the 
task force can use advice from 
medical specialists, but only if 
they are experienced in clinical 
epidemiology and primary care—and are 
thoroughly impartial. Recruiting advocates 
as reviewers would defeat the purpose of the 
task force, she says.
Time is running out for the Blackburn 
bill in this Congress. But if it fails this year, 
the appeal to shake up USPSTF by includ-
ing advocates may come back in 2013. 
Science recently spoke with Moyer about 
her role, her task force’s recent fame, and 
its future. Her answers have been edited for 
brevity and clarity. 
–ELIOT MARSHALL
Q: How did you get into this fi eld?
V.M.: I think I got into evidence-based medi-
cine because I tend to say, why are we doing 
this? (I have a journalist father and a scien-
tist mother.) I was extremely fortunate to go 
to an early workshop sponsored by McMas-
ter University, one of the birthplaces of 
evidence-based medicine. I got very 
involved. … I had written a paper about 
whether there was any evidence for what we 
do in pediatric checkups. I looked at pro-
cedures that were recommended by at least 
two august bodies for these checkups and 
dug up the evidence for them, and it turns 
out there’s not a lot of it. That doesn’t mean 
they don’t work.
Q: On the task force, was there concern 
about potential harms from preventive 
measures from the beginning?
V.M.: Yes, this was a new way of looking at 
things. We don’t just say, “Oh, prevention is 
wonderful.” As in all of medicine, you have 
to look at the upsides and the downsides, 
the benefi ts and the harms. … If you have 
someone who feels fi ne when they come 
into the offi ce, and you give them a screen-
ing test, you can’t make them feel better. 
The only thing you can do is make them feel 
worse. So we balance both the benefi ts and 
the harms of any preventive service. 
Q: Did a concern over cost drive this 
balancing act?
V.M.: That was not a big concern. It was 
more general. … You don’t want to do some-
thing that doesn’t work—that is just a waste 
of money. More important, it is a waste of 
time. In a clinical encounter, you don’t want 
to waste any of the limited time you have.
Q: Why was the recommendation against 
routine mammography controversial?
V.M.: The timing of the release coincided 
with health reform and the election. People 
were looking for a reason to be upset. … 
The health care reform bill said that if the 
USPSTF makes a recommendation with a 
grade of A or B, that service would be fi rst-
dollar covered [by health care providers]. 
Well, the task force didn’t give mammogra-
phy for women aged 40 to 49 an A or B, so 
people interpreted it to mean they wouldn’t 
be able to get [insurance] coverage. But that 











































Q: What did you take away from 
that experience?
V.M.: We learned that we were suddenly 
in the public eye, which has dramatically 
changed how we communicate. We have 
expanded the transparency of what we do 
and opportunities for input from the public 
and from other stakeholders.
Q: Did you have public 
comment before?
V.M.: We did not. … 
Everything went out for 
review to all kinds of 
people who we thought 
would be interested. 
Now it is put out on our 
Web site for anyone who 
wants to respond. We 
now invite public com-
ment at the point when 
we are starting to think 
about a topic, so the 
public can say, “Well, 
you are not asking the 
right questions.” … It 
really helps us to under-
stand what people are 
interested in, what they 
are concerned about. 
And other experts may look at an issue and 
say, “I think you should frame it differently.” 
Q: Did the PSA recommendation turn out to 
be as controversial as mammography?
V.M.: In some ways it is probably more 
controversial. The mammography recom-
mendation itself is not all that exciting. … 
It says: Think carefully because there are 
some downsides. … Don’t just leap into it. 
The PSA recommendation says: Don’t do 
it. That has been very controversial with the 
urologists and with some but not all advo-
cacy organizations. … We all have great 
hope [that preventive screening will work], 
and it is pretty painful to have that hope 
taken away.
Q: Have task force recommendations 
caused a change in behavior?
V.M.: There has been a change in mammog-
raphy frequency—that has been pretty well 
studied now over the last couple of years. 
And there have been a 
couple of studies look-
ing at the frequency of 
PSA [tests]. And [both] 
have gone down a little 
bit.
Q: Does it take a long 
time for recommenda-
tions to be acknow-
ledged?
V.M.: Absolutely. We 
shouldn’t be surprised 
by this. There are tons 
and tons of data out there 
on how long it takes for 
changes in health care to 
really take hold in prac-
tice. There was a study 
decades ago that’s always 
quoted that says it takes 
18 years to get anything new into practice—
that may not be exactly accurate, but it is true 
that change is hard and it takes a long time. 
Q: There’s a bill in Congress mandating 
that medical specialists be included on 
USPSTF panels. What do you think of it?
V.M.: It is important to recognize that … we 
[at USPSTF] already do have the appropri-
ate specialists on the panel: specialists in 
primary care and in evaluating science. Our 
recommendations are addressed to primary 
care clinicians about people who visit their 
generalists without specifi c concerns; these 
are not people who are going to specialists 
with a concern. If you put advocates on the 
panel, all you’re doing is asking for advo-
cacy, not science. 
Q: How much should task force 
work be linked to policy, such as 
spending decisions?
V.M.: In many countries—England is a 
good example—the body that does the type 
of work we do is directly linked to policy 
decisions. In this country, that doesn’t go 
as well. … We do not do cost-effectiveness 
analysis. That is a scientifi c fi eld in and of 
itself, and it’s very resource-intensive. We 
don’t do that. 
Q: Some say it would be a mistake to link 
the scientifi c review and policy decisions 
because the science would suffer.
V.M.: That tends to be right. … We don’t 
ignore the fact that there are [financial] 
costs associated with things, and we partic-
ularly consider cost to the individual to be a 
potential harm, but not in an explicit quan-
titative way. We do consider the fact that a 
false-positive test not only ends up requir-
ing in many instances invasive and unpleas-
ant procedures to determine that it was a 
false positive, but it can also be costly to 
the individual in time and money. My most 
recent false-positive mammogram cost me 
$2000 out of pocket, because insurance 
only covers the mammogram; it doesn’t 
cover the biopsy. Two thousand dollars is 
real money. Our purpose is not to save the 
system money. Our purpose is to improve 
the health of all Americans.
Q: Will the task force always be in the 
middle of controversy?
V.M.: Probably. And that’s OK. Somebody 
needs to be looking at the things that we 
[physicians] always do with a critical eye. 
Screening shocker. The task force’s deci-
sion on mammography upset many groups.
In response 
to a 1964 report on smoking by the Sur-
geon General, the United States became 
the fi rst country to mandate health-haz-
ard warnings for cigarettes and other 
tobacco products. Other countries have 
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There’s frequently 
debate about whether a screening method saves 
lives, but few doubt the effectiveness of one 
widely used method: the phenylketonuria (PKU) 
test now given to newborns in many industrial-
ized countries. Often part of an arsenal of other 
newborn assays, the PKU test checks whether 
an infant has a toxic buildup of the amino acid 
phenylalanine, which can lead to mental retar-
dation and other medical problems. If PKU is 
detected in a newborn, the infant can be given a 
specialized diet and avoid most health effects.
BABY SAFEGUARD: TOBACCO WARNING: The addition of folic acid to 
breads, grains, fl our, and other food products in 
many industrialized countries has been credited 
with reducing the number of babies born with 
neural tube defects. The U.S. Food and Drug 
Administration announced in 1996 that it would 
begin requiring folic acid fortifi cation in certain 
foods, and a few other countries have taken the 
same action. Similarly, niacin has been volun-
tarily added to enriched fl our in some countries 
to help ward off pellagra, the sometimes fatal 
disease caused by a B vitamin defi ciency.
FLOUR POWER:
C
R
E
D
IT
S
 (
T
O
P
 T
O
 B
O
T
T
O
M
):
 I
S
T
O
C
K
P
H
O
T
O
.C
O
M
; 
C
O
R
B
IS
Published by AAAS
 o
n 
S
ep
te
m
be
r 
27
, 2
01
2
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fr
om
 
